Vivus stock falls as company raises $202m in predicted offering: Chelsea next?
This article was originally published in Scrip
A public offering of Vivus stock predicted on Monday by Scrip saw the company raise $202.5 million to help usher its obesity drug Qnexa towards its PDUFA date with the FDA in April. The underwritten offer of 8.5 million shares at $22.50 prompted a fall in Vivus' share price of 11%, a move also predicted by Scrip.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.